[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"delayed-graft-function\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:delayed-graft-function":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,54,83,113,135],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100648757","the-impact-of-intraoperative-diuretic-use-on-delayed-graft-function-following-deceased-donor-renal-transplantation-100648757",false,"NCT07726134","The Impact of Intraoperative Diuretic Use on Delayed Graft Function Following Deceased Donor Renal Transplantation","A Pilot Randomized, Surgeon-blinded, Trial of Intraoperative Furosemide Versus Mannitol Among Deceased Donor Kidney Transplant Recipients","Inclusion Criteria:\n\n1. Age \\>18 years;\n2. Patient is scheduled to receive a deceased-donor kidney transplant (including both NDD and DCD donors)\n3. Patient is willing and able to provide written and informed consent, or a substitute decision maker (SDM) is available to sign on the patient's behalf\n\nExclusion Criteria:\n\n1. Patient is receiving another organ at the time of their kidney transplant (e.g., simultaneous kidney-pancreas or kidney-liver)\n2. Known allergy or contraindication to mannitol or furosemide\n3. Inability to provide informed consent\n4. Pediatric recipients (\\\u003C18 years of age)\n5. Previously enrolled in this clinical trial","ALL","18 Years",{"count":19,"type":20},160,"ESTIMATED","INTERVENTIONAL",[23],"NA","Delayed graft function, defined as the need for dialysis within seven days of kidney transplantation, is a common complication affecting deceased-donor kidney transplant recipients. It is associated with prolonged hospitalization, increased healthcare costs, higher rates of acute rejection, and poorer long-term graft survival. Intraoperative diuretics are routinely administered during kidney transplant surgery to promote early urine output and protect the kidney from injury during reperfusion. The two most commonly used agents are furosemide and mannitol. Despite decades of clinical use, no prospective randomized trial has directly compared these two medications, and practice remains highly variable across centres and individual surgeons. This single-centre, prospective, randomized, surgeon-blinded pilot trial will enroll 240 deceased-donor kidney transplant recipients at London Health Sciences Centre. Participants will be randomized in a 1:1 ratio, stratified by donor type, to receive either intraoperative furosemide or intraoperative mannitol. The primary feasibility outcomes include recruitment rate. The primary clinical outcome is the incidence of delayed graft function. Secondary outcomes include serum creatinine trajectory, urine output, dialysis requirements, perioperative complications, length of stay, and one-year graft and patient survival. This pilot trial will provide feasibility data and effect-size estimates necessary to inform the design of a future definitive multicentre randomized controlled trial.",[26,27],"Delayed Graft Function","Kidney Transplantation",[29,30,31,32,33,34,35,36,37,38,39,40],"Furosemide","Lasix","Mannitol","Intraoperative diuretics","Kidney transplantation","Renal transplantation","Deceased donor kidney transplantation","Delayed graft function","DGF","Early graft function","Ischemia-reperfusion injury","Kidney allograft","NOT_YET_RECRUITING","2026-07-20",{"date":44,"type":45},"2026-07-24","ACTUAL",{"date":47,"type":20},"2026-08",{"date":49,"type":20},"2028-12",{"name":51,"class":52},"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","OTHER",1,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":62,"targetDuration":4,"studyType":21,"phases":64,"briefSummary":66,"conditions":67,"keywords":69,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":82},"100579938","phase-3-double-blind-randomized-placebo-controlled-multicenter-study-to-evaluate-the-efficacy-and-safety-of-ravulizumab-administered-intravenously-in-adult-participants-at-high-risk-of-delayed-graft-function-after-kidney-transplantation-100579938","NCT06830798","Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation","A Phase 3, Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation","AWAKE","Inclusion Criteria:\n\n* ≥ 18 years of age at the time of signing the informed consent\n* Diagnosed with Dialysis-dependent End-Stage Kidney Disease (ESKD)\n* A candidate for kidney transplant from:\n\n  1. Donation after Circulatory Death (DCD) donor\n  2. High-risk Donation after Brain Death (DBD) donor\n\nExclusion Criteria:\n\n* Is to receive a kidney from a donor with category I,II,IV and V Maastricht Classification\n* Diagnosed with Acute Kidney Injury (AKI) of Stage 3 severity according to the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines.",{"count":63,"type":20},450,[65],"PHASE3","The primary objective of this study is to demonstrate the efficacy of ravulizumab vs placebo in reducing the severity of DGF as measured by time to freedom from dialysis in adult participants who are at high risk of DGF after undergoing transplant of deceased donor kidney.",[26,37,68],"Kidney Transplant",[26,37,68,70],"Ravulizumab","RECRUITING","2026-06-17",{"date":74,"type":45},"2026-06-18",{"date":76,"type":45},"2025-05-19",{"date":78,"type":20},"2028-08-30",{"name":80,"class":81},"Alexion Pharmaceuticals, Inc.","INDUSTRY",130,{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":4,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":90,"enrollmentInfo":91,"targetDuration":4,"studyType":21,"phases":93,"briefSummary":96,"conditions":97,"keywords":99,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":53},"100362920","phase-1-safety-and-efficacy-of-treprostinil-remodulin-in-reducing-ischemia-reperfusion-injury-during-kidney-transplantation-100362920","NCT04005469","Safety and Efficacy of Treprostinil (Remodulin®) In Reducing Ischemia-Reperfusion Injury During Kidney Transplantation","A Phase I\u002FII Study Evaluating the Preliminary Safety and Efficacy of Treprostinil (Remodulin®) In Reducing Ischemia-Reperfusion Injury During De Novo Adult Kidney Transplantation","Inclusion Criteria:\n\n1. Male and female patients who will receive a deceased donor kidney aged 18 to 65 (inclusive) and are currently on the active transplant list at RIH.\n2. Documentation of a diabetes diagnosis as evidenced by one or more clinical features consistent will be noted for all patients.\n3. Written informed consent (and assent when applicable) obtained from subject or subject's legal representative and ability for subject to comply with the requirements of the study.\n\nExclusion Criteria:\n\n1. Under the age of 18 years\n2. Difficult venous access\n3. BMI \\> 40 kg\u002Fm2\n4. Patients with severe clinical gastroparesis as determined by repeated vomiting\n5. Prior GI surgery except for cholecystectomy, appendectomy, or Nissen fundoplication\n6. Known or history of inflammatory bowel disease or bezoars\n7. History of diverticulitis, diverticular stricture, and other intestinal strictures\n8. Be receiving any investigational drug other than treprostinil or participating in any other investigational study\n9. Be receiving any prostanoid therapy to treat portopulmonary hypertension\n10. Have any known hypersensitivity to prostaglandins, prostacyclin or treprostinil\n11. Have had a failed kidney transplant within the previous 180 days\n12. Be receiving any non-standard immunosuppression protocol or other non-standard treatment that could affect interpretation of the study results\n13. Those with significant cardiovascular disease including treatment with inotropes\n14. If female, be pregnant or nursing (confirmed by urine test)\n15. Presence of a condition or abnormality that in the opinion of the Investigators that would compromise the safety of the patient or the quality of the data","75 Years",{"count":92,"type":20},20,[94,95],"PHASE1","PHASE2","The objectives of this study are to test the preliminary safety and efficacy of a two-day peri-operative course of treprostinil in reducing ischemia-reperfusion injury in adult patients receiving a deceased donor kidney transplantation. Treprostinil, a prostacyclin analog, is expected to facilitate the restoration of blood supply to the revascularized kidney graft via its vasodilatory actions, well characterized protective effects, and longer elimination half-life. These properties and actions of treprostinil make it a strong drug candidate to reduce kidney graft dysfunction during kidney transplantation. An anticipated 20 participants undergoing deceased donor kidney transplant will be hospitalized and intensively monitored during an entire two-day Treatment Phase. An IV infusion using a dedicated central venous line will be used to administer treprostinil commencing approximately 2-3 hours before transplantation of the kidney graft and will continue for approximately 48 hours after completion of the transplant surgery. The primary endpoints include the safety and efficacy of treprostinil, with secondary endpoints including the evaluation of both biochemical and clinical endpoints post-transplantation.",[98,26],"Ischemia Reperfusion Injury",[39,100,101,102,103],"kidney transplantation","prostacyclin","treprostinil","delayed graft function","2026-04-20",{"date":106,"type":45},"2026-04-23",{"date":108,"type":45},"2020-11-13",{"date":110,"type":20},"2028-06-30",{"name":112,"class":52},"Rhode Island Hospital",{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":4,"eligibilityCriteria":119,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":120,"targetDuration":4,"studyType":21,"phases":122,"briefSummary":123,"conditions":124,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":134},"100614133","phase-1-the-effects-of-vonoprazan-fumarate-on-dgf-incidence-in-dd-kidney-transplant-recipients-100614133","NCT07275632","The Effects of Vonoprazan Fumarate on DGF Incidence in DD Kidney Transplant Recipients","A Multicenter, Single-Arm, Exploratory Study Evaluating the Effect of Perioperative Oral Vonoprazan Fumarate on the Incidence of Delayed Graft Function in Deceased Donor Kidney Transplant Recipients","Inclusion Criteria:\n\n* Age ≥ 18 years at time of transplantation.\n* Undergoing first-time deceased-donor kidney transplantation.\n* No administration of proton-competitive acid blockers (P-CABs) in the 1 month prior to transplantation.\n* Consent to receive the standard immunosuppressive therapy post-transplantation.\n* Ability and willingness to provide informed consent and comply with study procedures and follow-up.\n* Complete baseline clinical data available.\n\nExclusion Criteria:\n\n* Receiving a living-donor kidney transplant or multi-organ transplantation.\n* Previous history of any solid organ or cellular transplantation (with the exception of corneal transplants).\n* Intraoperative occurrence of hyperacute rejection or confirmed graft non-function (e.g., renal artery thrombosis).\n* Presence of high risk for primary graft non-function (e.g., severe injury to the transplant renal artery).\n* Severe postoperative intestinal obstruction requiring prolonged fasting or inability to take oral medication in perioperative period.\n* Known history of hypersensitivity to vonoprazan fumarate or any of its excipients.\n* Subjects with severe hepatic impairment (Child-Pugh Class C).\n* Concomitant use of strong CYP3A4 inhibitors (e.g., ritonavir, clarithromycin).\n* Current therapy with atazanavir or rilpivirine.\n* Any other condition deemed by the investigator to be inappropriate for study participation (e.g., uncontrolled active infection, severe peptic ulcer, pregnancy or lactation).",{"count":121,"type":20},47,[94,95],"This is an exploratory, multicenter, single-arm study designed to evaluate the efficacy of perioperative Vonoprazan Fumarate in reducing the incidence of Delayed Graft Function (DGF) in deceased-donor kidney transplant recipients. DGF is a common early complication that significantly impacts graft function and long-term transplant survival. This study aims to explore how Vonoprazan Fumarate, a potassium-competitive acid blocker (P-CAB), can potentially improve macrophage phagocytic function, reduce kidney inflammation, and enhance early kidney function recovery.\n\nPatients aged 18 years and older who are undergoing first-time deceased-donor kidney transplantation will be enrolled. Vonoprazan Fumarate will be administered daily starting on the day of transplantation and continuing for seven days post-surgery. The primary endpoint is DGF incidence, while secondary endpoints include kidney function recovery, serum creatinine reduction, estimated glomerular filtration rate, and safety assessments. Adverse events will be monitored, and the study will also explore potential biomarkers for inflammation and graft function.\n\nThe study is expected to provide insights into a potential new therapeutic strategy to reduce DGF and improve early kidney transplant outcomes, potentially benefiting future kidney transplant patients by offering a safer and more effective perioperative treatment option.",[26,27],"2025-12-17",{"date":127,"type":45},"2025-12-23",{"date":129,"type":45},"2025-12-10",{"date":131,"type":20},"2026-12-31",{"name":133,"class":52},"First Affiliated Hospital of Chongqing Medical University",2,{"id":136,"slug":137,"hasResults":11,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":4,"eligibilityCriteria":141,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":142,"targetDuration":4,"studyType":21,"phases":144,"briefSummary":145,"conditions":146,"keywords":148,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":161},"100544309","norepinephrine-infusion-combined-with-goal-directed-fluid-therapy-in-patients-undergoing-kidney-transplantations-100544309","NCT06367205","Norepinephrine Infusion Combined With Goal-directed Fluid Therapy in Patients Undergoing Kidney Transplantations","Norepinephrine Infusion Combined With Goal-directed Fluid Therapy Reduces Delayed Graft Function Incidence in Patients Undergoing Kidney Transplantations: a Randomized Multicenter Clinical Trial","Inclusion Criteria:\n\n1. Recipients aged 18 years or older\n2. Scheduled to undergo kidney transplantations under general anesthesia\n3. Cadaveric kidney transplantations\n4. Sign the informed consent form\n\nExclusion Criteria:\n\n1. Donors aged under 18 years\n2. Donor kidneys classified as Maastricht category I or II\n3. Contraindications to radial artery catheterization\n4. Pregnancy\n5. Cardiac dysfunction (exercise tolerance less than 4 METS)\n6. Severe liver dysfunction (Child Pugh C-grade)\n7. Respiratory diseases with tidal volume intolerance exceeding 8ml\u002Fkg\n8. Severe arrhythmias, including atrial fibrillation, frequent atrial or ventricular premature beats, moderate or severe aortic and mitral regurgitation\n9. Double-kidney transplantations\n10. Simultaneous organ or additional surgeries during kidney transplantations\n11. Repeat kidney transplantations\n12. Concurrent participation in other clinical trials\n13. Patients deemed ineligible by researchers",{"count":143,"type":20},380,[23],"Delayed graft function (DGF), delineated by the necessity for dialytic intervention within the initial week post-transplantation, afflicts approximately 20%-50% of recipients. The primary objective of this study is to investigate the potential efficacy of norepinephrine infusion in conjunction with goal-directed fluid therapy (GDFT) in mitigating the occurrence of DGF among individuals undergoing kidney transplantations. The findings of this investigation have the potential to advance the field of perioperative care in kidney transplantations by providing insights into optimized management strategies.",[26,147,27],"End Stage Renal Disease",[149,150,151],"Norepinephrine","Goal-directed fluid therapy","Randomized controlled trial","2024-04-15",{"date":154,"type":45},"2024-04-16",{"date":156,"type":45},"2024-03-01",{"date":158,"type":20},"2026-06-30",{"name":160,"class":52},"RenJi Hospital",3]